OverviewSuggest Edit

F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system. As a result serious fungal infections continue to increase. The focus at F2G is to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates. Through its proprietary genomics technology and antifungal screening activities F2G has identified a number of novel chemical series with potent antifungal activity. These novel series form the basis of the F2G development pipeline. Currently F2G is advancing its F3 series of anti mould compounds. This is a novel class of antifungal agent, which acts through a completely new mechanism different from all currently marketed drugs. The F3 series displays highly potent activity against clinically relevant aspergilli and many other important pathogenic moulds. F2G has a dedicated team of experienced scientists from a wide variety of research and drug development backgrounds supported by an experienced management group with many years experience of drug development within the Pharmaceutical industry.
TypePrivate
Founded1998
HQEccles, GB
Websitef2g.com

Latest Updates

Employees (est.) (Oct 2021)40(+9%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at F2G

Mike Birch

Mike Birch

COO
Ian Nicholson

Ian Nicholson

Chief Executive Officer
Ralf Schmid

Ralf Schmid

Chief Financial Officer
John H. Rex

John H. Rex

Chief Medical Officer
Tony Kennedy

Tony Kennedy

Chief Scientific & Development Officer
Show more

F2G Office Locations

F2G has an office in Eccles
Eccles, GB (HQ)
Lankro Way
Show all (1)

F2G Financials and Metrics

Summary Metrics

Founding Date

1998

F2G total Funding

$213.3 m

F2G latest funding size

$60.8 m

Time since last funding

a year ago

F2G investors

F2G's latest funding round in August 2020 was reported to be $60.8 m. In total, F2G has raised $213.3 m
Show all financial metrics

F2G Revenue

GBP

Net income (FY, 2018)

4.4m

EBITDA (FY, 2018)

(11.5m)

EBIT (FY, 2018)

(11.5m)

Cash (31-Dec-2018)

7.1m
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cost of goods sold

3.4m3.9m14.4m6.8m9.5m

Operating expense total

620.9k336.9k1.0m1.8m1.9m

EBITDA

(4.2m)(15.4m)(8.6m)(11.5m)

EBIT

(4.0m)(4.3m)(15.5m)(8.7m)(11.5m)
GBPFY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.7k327.7k92.097.1k210.3k190.0k564.0k717.0k242.4k326.1k340.1k288.6k1.9m2.1m4.3m6.3m8.6m6.8m7.1m

Accounts Receivable

387.1k386.3k345.9k341.0k241.8k312.6k454.8k

Current Assets

2.014.8k357.5k161.2k377.8k354.6k482.7k828.0k1.1m628.7k672.0k681.0k530.4k2.3m2.6m5.0m7.2m13.0m8.8m9.6m

PP&E

19.0k84.4k251.8k293.6k441.9k261.4k131.0k49.6k15.4k5.6k3.0k3.1k2.6k10.5k34.4k24.1k23.7k17.0k16.0k
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(4.8m)(4.2m)(13.9m)(5.9m)4.4m

Cash From Operating Activities

(3.2m)(4.0m)(14.3m)(4.4m)(9.8m)

Cash From Financing Activities

5.5m6.0m16.7m2.5m10.1m

Net Change in Cash

2.2m2.0m2.3m(1.8m)276.7k
GBPFY, 1999

Financial Leverage

1 x
Show all financial metrics

F2G Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

F2G Online and Social Media Presence

Embed Graph

F2G News and Updates

F2G appoints Camilla Soenderby to Board of Directors

MANCHESTER, England, PRINCETON, N.J. and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive...

Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd

MANCHESTER, England and VIENNA, April 12, 2021 /PRNewswire/ -- F2G Limited ("F2G"), a clinical-stage biopharmaceutical company focused on life threatening fungal diseases, announces that Francesco Maria Lavino has been appointed Chief Executive Officer (CEO) and member of the Board of F2G....

Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing

COPENHAGEN, Denmark, Aug. 12, 2020 /PRNewswire/ -- Novo Ventures, the ventures arm of Novo Holdings, today announces that its portfolio company, F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, has secured US $60.8...

F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent

MANCHESTER, England and VIENNA, Aug. 12, 2020 /PRNewswire/ -- F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that it has secured US $60.8 million in new financing from new and existing investors. The...

F2G Receives US FDA Orphan Drug Designation for Olorofim

MANCHESTER, England and VIENNA, Austria, Mar. 9, 2020 /PRNewswire/ -- F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

MANCHESTER, England and VIENNA, Nov. 11, 2019 /PRNewswire/ -- F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy...
Show more

F2G Blogs

F2G expands investor syndicate and progresses Phase IIb study for novel antifungal

F2G expands investor syndicate and progresses Phase IIb study for novel antifungal ● New investor […]

F2G to Present at the Evercore ISI HealthCONx Conference

F2G to Present at the Evercore ISI HealthCONx Conference F2G will be present in the […]

EU supports F2G Biotech in Austria with EUR 24 million for antifungal research and innovation

PRESS RELEASE Luxembourg, 22 November 2018 EU supports F2G Biotech in Austria with EUR 24 […]

F2G Frequently Asked Questions

  • When was F2G founded?

    F2G was founded in 1998.

  • Who are F2G key executives?

    F2G's key executives are Mike Birch, Ian Nicholson and Ralf Schmid.

  • How many employees does F2G have?

    F2G has 40 employees.

  • Who are F2G competitors?

    Competitors of F2G include Macleods Pharmaceuticals, Alkem Laboratories and McKesson Europe.

  • Where is F2G headquarters?

    F2G headquarters is located at Lankro Way, Eccles.

  • Where are F2G offices?

    F2G has an office in Eccles.

  • How many offices does F2G have?

    F2G has 1 office.